PR Web (press release)Engineered T-Cell Receptor in Fusion Proteins, Antibodies & Cells Industry …PR Web (press release)Therapeutic monoclonal antibodies have become an increasingly successful treatment modality with sales of US$ 65 bln in the ye…
|
Findings in Amino Acids Reported from Novartis Pharma
HispanicBusiness.com Our news journalists obtained a quote from the research from Novartis Pharma, “Here we report the characterization of a proposed biosimilar rituximab (GP2013) and originator rituximab. To compare GP2013 with originator rituximab using an extensive … |
Drug Discovery & Development |
Why Antibody Lots Differ Significantly
Drug Discovery & Development Since antibodies first attained prominence as research reagents in modern biological science labs, researchers have been perplexed as to why one production lot can differ significantly from the next, in terms of performance. Poor antibody performance … |
Nature World NewsNew Artificial Protein Mimics A Part Of The HIV Outer CoatRedOrbitA team of scientists at Duke Medicine and Memorial Sloan-Kettering Cancer Center has created an artificial protein coupled with a sugar molecule that mimics a key site o…
The hitchhiker antigen: Cause for concern?Eureka! Science NewsSince antibodies first attained prominence as research reagents in modern biological science labs, researchers have been perplexed as to why one production lot can differ significantly from …
OncLiveNovel B-Cell Receptor Signaling Inhibitors Show PromiseOncLiveMany of the patients in these studies were heavily pretreated, and many did not achieve objective responses, so the interest is in combining it with other active agents, such as benda…
|
Artificial protein mimics a part of the HIV outer coat
R & D Magazine A team of scientists at Duke Medicine and Memorial Sloan-Kettering Cancer Center has created an artificial protein coupled with a sugar molecule that mimics a key site on the outer coat of HIV where antibodies can bind to neutralize a wide variety of … |
Research and Markets: The Engineered T-Cell Receptor in Fusion Proteins …Fort Mills TimesTherapeutic monoclonal antibodies have become an increasingly successful treatment modality with sales of US$ 65 bln in the year 2012 and with an average (contin…
RESEARCH AND MARKETS: The Engineered T-Cell Receptor in Fusion …4-traders (press release)Therapeutic monoclonal antibodies have become an increasingly successful treatment modality with sales of US$ 65 bln in the year 2012 and with an average (contin…
Research and Markets: The Engineered T-Cell Receptor in Fusion Proteins …Business Wire (press release)Therapeutic monoclonal antibodies have become an increasingly successful treatment modality with sales of US$ 65 bln in the year 2012 and with an av…